Publications: Stephen Ezell

For policymakers to bolster their regional innovation capacity and global competitiveness, they first must know where they stand. This report benchmarks 48 regions across Albania, Bosnia and Herzegovina, North Macedonia, and Serbia on 13 commonly available innovation indicators.

U.S. automotive competitiveness has severely faltered. The federal government needs a comprehensive national strategy to revitalize the industry’s competitiveness, especially in the face of Chinese EVs.

The competitiveness of the auto industry of the United States has waxed and waned over the past 60 years and is clearly not the globally dominant behemoth it once was. To bolster the industry’s competitiveness, policymakers first must understand why it has faltered and the challenges it faces moving forward.

The Trump administration’s Section 232 pharmaceutical tariffs will needlessly raise drug costs, harm U.S. patients, and undermine both domestic manufacturing and global biopharmaceutical innovation, while better policy options exist to strengthen the industry without these damaging side effects.

Boosting U.S. competitiveness in national power industries is necessary, but not sufficient to avoid losing to China. America also must take measures to slow the PRC’s progress toward global dominance. This report provides more than 100 actionable recommendations for the administration and Congress. Western allies should take many of the same steps.

To win the techno-economic competition with China, America must be able to assess the factors impacting the global competitiveness of its advanced-technology industries. Using the auto industry as a template, U.S. competitiveness has faltered considerably.

CFIUS’ procedures need to be strengthened to ensure that Chinese entities, particularly those influenced or backed by Chinese government influence or funding, cannot acquire U.S. companies or technology that could harm America’s economic or national security.

Europe once led the world in biopharmaceutical innovation, but it lost ground after adopting policies that weakened incentives for R&D and innovation. America must learn from Europe’s experience to preserve its own biopharma leadership and the related economic benefits and access to the most innovative drugs.

The United States should use MC14 to push for a WTO that actively promotes fair market competition—not one that passively accepts non-market policies, overcapacity, and coercive distortions that are undermining the global trading system.

The international reference pricing-based GUARD model lacks a sound premise for its rationale, is fundamentally flawed in its design, and should be withdrawn in full by CMS.